Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Baillie Gifford -Global Alpha. This analysis is provided for institutional research purposes only and is not investment advice.
"Strong Q3 performance driven by AI leaders like AppLovin and biotechnology recovery play Medpace. Healthcare holdings faced headwinds from rising costs and GLP-1 competition."
Baillie Gifford's Global Alpha Fund delivered strong performance in Q3 2025, driven by AI beneficiaries and datacenter infrastructure buildout. Top contributors included AppLovin, whose AI-powered advertising platform AXON drove over 70% sales growth, and Medpace, which benefits from recovering biotechnology funding creating pent-up demand for clinical trials. Shopify reinforced its retail operating system leadership with 40% GMV growth in Europe. Key detractors included Elevance Health, facing rising medical costs in Medicaid plans, and Novo Nordisk, which cut GLP-1 drug guidance due to competitive pressure from copycat treatments. The fund added four new positions including MSCI, Coinbase, and The Ensign Group, funded by sales of UnitedHealth, BHP Group, and others. The manager emphasizes focusing on company quality and characteristics globally rather than aggregate market valuations, positioning for secular trends in AI adoption, biotechnology recovery, and e-commerce expansion while taking advantage of temporary dislocations in healthcare and pharmaceuticals.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
High conviction demonstrated through active portfolio rotation, maintaining positions in challenged names based on long-term thesis, and clear articulation of multi-year recovery themes. The manager shows strong conviction in AI beneficiaries and biotechnology recovery while expressing confidence in company-specific turnaround stories.
Growth Outlook
The manager expresses cautious optimism about market conditions, noting that markets continue to rally and reach new all-time highs led by AI enthusiasm. However, the tone is measured rather than exuberant, acknowledging the familiar feel of current conditions and reframing questions about US market dominance in a balanced way.
Risk Appetite
The portfolio shows moderate risk-taking through active rotation, adding four new positions including higher-risk assets like Coinbase while maintaining conviction in challenged healthcare names. The manager demonstrates selective risk appetite by holding positions facing temporary headwinds based on long-term value beliefs.
Capital Deployment
Moderate deployment activity with four new additions funded by six sales, suggesting balanced rotation rather than aggressive net deployment. The activity indicates selective capital reallocation based on opportunity assessment rather than broad-based deployment or de-risking.
Forward Guidance
Forward guidance is constructive but measured, emphasizing focus on company quality over market timing. The manager expresses confidence in multi-year recovery cycles for biotechnology and maintains conviction in challenged positions, suggesting a positive but patient approach to capital deployment.
Language Signal
Language contains balanced mix of opportunity-focused terms like 'turbo-charging growth', 'reinforced leadership', and 'strong recovery prospects' alongside risk acknowledgment. The tone is professional and measured rather than overtly bullish or bearish, with emphasis on long-term value creation.
Perceived Risk
Moderate risk perception with acknowledgment of specific sector challenges including rising medical costs, regulatory uncertainty, and competitive pressures. The manager identifies clear headwinds but frames them as temporary rather than systemic, suggesting measured risk awareness without elevated concern.
Opportunity Density
Good opportunity density evidenced by identification of multi-year recovery themes in biotechnology, AI adoption trends, and global e-commerce expansion. The manager demonstrates ability to find attractive opportunities across sectors and geographies while taking advantage of temporary dislocations.
Time Horizon
Long-term orientation clearly demonstrated through references to multi-year recovery cycles, maintaining positions through temporary headwinds, and focus on secular trends rather than near-term catalysts. The emphasis on company quality over market timing reinforces patient capital approach.
